-
1 × $137.12
Subtotal: $137.12
RetaCag
$83.14
RetaCag is a dual-peptide research blend containing Retatrutide Acetate (5 mg) and Cagrilintide Acetate (1 mg), developed for studies into complementary incretin–amylin receptor pharmacology, metabolic regulation, and energy homeostasis. Retatrutide is a triagonist targeting GLP-1, GIP, and glucagon receptors to enhance glucose control, increase energy expenditure, and modulate appetite, while Cagrilintide is a long-acting amylin receptor agonist designed to promote satiety and delay gastric emptying. Together, these agents enable research into multi-hormonal approaches for weight regulation, glycemic control, and metabolic disease modeling.
Supplied as a lyophilized acetate blend, RetaCag is optimized for sterility, stability, and extended shelf life.
Provided in a 3 mL vial, this combination is ideal for studies examining synergistic receptor activation, anorectic effects, and long-acting peptide pharmacokinetics.
Solubility: RetaCag is soluble in sterile water, dilute acetic acid, or aqueous buffers at pH 5–7.
For laboratory research use only. Not for human or veterinary applications.
Description
RetaCag (Retatrutide + Cagrilintide) Acetate Blend
Contents (per vial):
- 5 mg Retatrutide Acetate
- 1 mg Cagrilintide Acetate
Structural Characteristics:
RetaCag combines two advanced, long-acting peptide analogs for multi-receptor metabolic research:
- Retatrutide – a lipidated synthetic triagonist activating GLP-1, GIP, and glucagon receptors, incorporating a C20 fatty diacid at Lys20 via an AEEA linker for enhanced albumin binding and prolonged activity.
- Cagrilintide – a 37-amino acid amylin receptor agonist analog conjugated with a C20 fatty diacid for extended half-life and sustained receptor activation.
This combination offers complementary mechanisms to influence metabolic, satiety, and energy regulation pathways.
Mechanism of Action (Research Context):
RetaCag is studied for potential synergistic effects in:
- Appetite regulation and satiety signaling models
- Glycemic control and insulin sensitivity studies
- Body weight reduction and energy expenditure research
- Hepatic fat metabolism and obesity-related investigations
Synthesis and Quality Control:
- Manufactured via solid-phase peptide synthesis (SPPS)
- Each peptide purified to ≥98% by HPLC
- Identity verified via Mass Spectrometry (MS)
Product Details:
- Form: Lyophilized acetate salt blend
- Appearance: White to off-white powder
- Supplied in: 3mL sterile vial
Solubility & Reconstitution:
Soluble in sterile water, dilute acetic acid, or aqueous buffers at pH 5–7.
- Gently swirl to dissolve; avoid vigorous shaking
- Protect from high pH and oxidation to maintain peptide integrity
Storage & Handling:
- Store lyophilized powder at –20°C, away from light and moisture
- After reconstitution, refrigerate at 2–8°C for up to 30 days
- For long-term storage, aliquot and freeze at –20°C
- Avoid repeated freeze-thaw cycles
Disclaimer:
For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic applications.
Additional information
| Weight | .06 lbs |
|---|---|
| Dimensions | .5 × .5 × 1 in |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.